Table 3.
Patient | Dose Erlotinib (mg) | Duration Treatment Planned | Duration Treatment Received | Neck CT% change in max. diameter | Day of Early In-Treatment PET/CT | Early In-Treatment PET/CT % change in SUV | Post-treatment PET/CT % change in SUV | Erlotinib (ng/mL) | OSI-420 (ng/mL) |
---|---|---|---|---|---|---|---|---|---|
1 | 150 | 17 | 17 | -37 | 7 | -26 | -26 | NIA | N/A |
2 | 150 | 20 | 20 | -28 | 6 | -28 | -10 | 3407.6 | 82.75 |
3 | 150 | 14 | 14 | -22 | 4 | -27 | -43 | 7520.85 | 533.1 |
4 | 150 | 15 | 15 | -21 | 6 | -38 | -55 | NIA | N/A |
5 | 150 | 21 | 21 | -21 | 6 | -52 | -37 | 113.95 | 2.65 |
6 | 150 | 26 | 26 | -16 | 6 | -32 | -40 | 1635.35 | 83.25 |
7 | 150 | 14 | 11 | -13 | 6 | -13 | NIA | NIA | N/A |
8 | 150 | 14 | 14 | -10 | 6 | -27 | -12 | 163ll.15 | 22.5 |
9 | 150 | 18 | 18 | 0 | 6 | 5 | +9 | 706.85 | 14.65 |
10 | 300 | 27 | 27 | -45 | 6 | -43 | -70 | 6023.4 | 166.05 |
11 | 300 | 15 | 15 | -27 | 5 | -70 | -65 | 3753.15 | 46.25 |
12 | 300 | 22 | 20 | -25 | 6 | -39 | -49 | 325.8 | 0.5 |
13 | 300 | 18 | 18 | -24 | 7 | -43 | -43 | NIA | N/A |
14 | 300 | 14 | 14 | -21 | 6 | -56 | -52 | 3955.8 | 105.55 |
15 | 300 | 16 | 16 | -21 | 6 | -25 | -32 | 1964.9 | 33.2 |
16 | 300 | 20 | 20 | -10 | 6 | -25 | -25 | 3172.05 | 107.65 |
17 | 300 | 21 | 21 | -10 | 6 | -25 | -20 | 598.85 | 0.75 |
18 | 300 | 25 | 25 | 0 | 6 | +84 | 67 | NIA | N/A |
19 | 300 | 14 | 14 | 0 | 6 | -2 | -5 | 212.35 | 0 |
20 | 150 | 17 | 12 | -20 (at 6 days) | 6 | -54 | refused | 1170.75 | 5.65 |
21 | 300 | 17 | 15 | -13 (at 6 days) | 6 | -54 | refused | 3775.85 | 101.75 |
22 | 300 | 17 | 11 | Not measurable | 9 | -52 | off protocol-no longer a candidate for surgery | N/A | |
23 | 150 | 15 | 4 | Removed from the protocol due to tumor complications | N/A | ||||
24 | Removed from the protocol due to non-compliance | N/A |
Pink - patients receiving 150 mg erlotinib; Cyan - patients receiving 300 mg erlotinib; Gray- patients without post-treatment PET/CT. N/A Not Available.